Market News & Trends
Albireo Pharma Announces New Phase 3 Data That Shows Durable Response to Odevixibat in a Rare Pediatric Liver Disease
Albireo Pharma, Inc. recently announced new data in progressive familial intrahepatic cholestasis (PFIC) confirming statistically significant reductions in serum bile acids (sBAs) and improvements in…
Beam Therapeutics Presents First Data Highlighting Base Editing Program for Glycogen Storage Disease Type Ia
Beam Therapeutics Inc. recently announced the company will present preclinical data from its liver-focused programs, including the first data highlighting its novel base-editing strategy for…
Cambrex to Invest $50 Million to Expand Multipurpose Large-Scale Manufacturing Capabilities in the US
Cambrex recently announced it is expanding its mid-scale and large-scale API manufacturing capacity in Charles City, Iowa. The $50+ million investment is designed to meet…
CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke
CalciMedica Inc. recently announced the publication of preclinical data demonstrating a pathological role for CRAC channel-mediated microglial calcium activity in ischemic brain injury in the…
BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial
BioAegis Therapeutics Inc. recently announced it has expanded its clinical trial in severe COVID-19 to additional sites in Europe. The study has recruited more than…
Apellis Announces FDA Acceptance & Priority Review of NDA
Apellis Pharmaceuticals, Inc. recently announced the US FDA has accepted and granted Priority Review designation for the New Drug Application (NDA) for pegcetacoplan for the treatment…
Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study of Nasal Spray Being Developed for COVID-19
Atossa Therapeutics, Inc. recently announced blinded preliminary results from its Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. AT-301…
IntelGenx Announces Issuance of US Patent for Novel Technology Applicable to Cannabis-Containing Oral Films
IntelGenx Corp., a leading oral drug delivery company, recently announced that the United States Patent and Trademark Office has issued US Patent 10,828,254, titled Oral…
XOMA Earns First Milestone Payment From 2018 Royalty Purchase Agreement
XOMA Corporation recently announced it has earned a $1-million milestone payment from Agenus Inc. related to Merck’s advancement of MK-4830 into a Phase 2 study…
Halberd Corporation Files for Patent Protection on Enhanced Nasal Spray to Prevent Covid-19
Halberd Corporation reported the filing of a Covid-19 provisional patent on an enhanced nasal spray. The application, Nasal Spray to Prevent the Transmission of Covid-19,…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….